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provement of visual acuity and FT was present in both 
groups during the 12 months following first treatment. No 
adverse effects were observed.  Conclusion: The combina-
tion of intravitreal bevacizumab or ranibizumab  with dexa-
methasone and full-fluence PDT for exudative AMD provid-
ed visual and anatomic improvement and a good safety pro-
file. Triple therapy may reduce the number of retreatments 
when compared to anti-VEGF alone. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 In past years photodynamic therapy (PDT) with verte-
porfin has shown to be effective for treatment of choroi-
dal neovascularization (CNV) in age-related macular de-
generation (AMD)  [1, 2] . Nevertheless, most cases require 
retreatment  [3, 4] , and reported benefits are a reduced 
risk of visual loss, rather than an improvement of best-
corrected visual acuity (BCVA)  [5] . Recently approved 
anti-vascular-endothelial-growth-factor (VEGF) anti-
bodies have shown to be effective in the treatment of 
CNV by determining an average increase in BCVA. Ra-
nibizumab is the antigen-binding fragment of a recombi-
nant humanized monoclonal antibody which presents a 
high affinity for and inhibits the activity of all active 
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 Abstract 
 Purpose: To evaluate the efficacy and safety of triple therapy 
with intravitreal anti-vascular-endothelial-growth-factor 
(VEGF) antibody, dexamethasone and verteporfin photody-
namic therapy (PDT) for exudative age-related macular de-
generation (AMD).  Methods: Retrospective, comparative, in-
terventional study. Records of treatment-naïve patients who 
received intravitreal bevacizumab or ranibizumab in mono-
therapy or in combination with dexamethasone and full-flu-
ence verteporfin PDT in triple therapy were reviewed. log-
MAR visual acuity, foveal thickness (FT) on optical coherence 
tomography, intraocular pressure and endophthalmitis oc-
currence were recorded.  Results: Sixty-one eyes were in-
cluded in the triple-therapy group, 40 eyes were included in 
the monotherapy group. The mean follow-up was 14.1  8 3.4 
months in the triple-therapy group and 16.3  8 4.1 months 
in the monotherapy group. The triple-therapy group en-
joyed a lower total number of treatments (1.92  8 0.44 vs. 3.12 
 8 0.37, p  ! 0.001) and a longer time before first retreatment 
(5.4  8 3.3 vs. 3.6  8 2.5 months, p = 0.001). A significant im-
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forms of VEGF-A  [6, 7] . Several reports have described 
the good safety and efficacy of intravitreal bevacizumab, 
an anti-VEGF monoclonal antibody approved for the in-
travenous treatment of metastatic cancer  [8–10] , which 
binds to all isoforms of VEGF and is still used today in 
this off-label indication because its cost is considerably 
lower than that of ranibizumab  [11] . However, treatment 
with anti-VEGF agents often requires intravitreal injec-
tions at regular 4- to 6-week intervals, requiring frequent 
follow-up visits and repeated exposure to the risk of en-
dophthalmitis  [8, 10, 12, 13] . The association between the 
direct angio-occlusive effect of verteporfin PDT with the 
anti-inflammatory effect of intravitreal dexamethasone 
and anti-VEGF has been previously reported  [14, 15] . 
However, only bevacizumab was administered, a reduced 
dose of verteporfin PDT was used, and no comparison 
with anti-VEGF monotherapy was done. Herein, we com-
pared anti-VEGF monotherapy and triple therapy with 
bevacizumab or ranibizumab in combination with dexa-
methasone and full-fluence verteporfin PDT in treat-
ment-naïve patients with exudative AMD. 
 Methods 
 The study followed the tenets of the Declaration of Helsinki 
and had Institutional Research Board approval. It was performed 
with informed consent and following all the guidelines required 
by the Ethics Committee.
 Medical records for consecutive patients with exudative AMD 
treated with intravitreal anti-VEGF in monotherapy or in combi-
nation with dexamethasone and full-fluence PDT at the Eye De-
partment of the University Hospital of Limoges from June 2006 to 
May 2009 were retrospectively identified. Inclusion criteria were 
subfoveal CNV due to AMD and no history of previous treatment 
in the studied eye. There was no restriction as to the type of CNV 
(predominantly classic, minimally classic or occult). Exclusion 
criteria were myopic degeneration, angioid streaks, presumed oc-
ular histoplasmosis, retinal angiomatous proliferation or polypoi-
dal choroidal vasculopathy, uncontrolled hypertension, recent 
myocardial infarction or cerebral vascular accident. 
 At baseline and at each following visit, Early Treatment Dia-
betic Retinopathy Study logMAR BCVA testing, slitlamp exami-
nation of the anterior segment, intraocular pressure measure-
ment and dilated fundus examination were performed. Mean 
thickness in the central 1,000-  m diameter area (foveal thick-
ness, FT) was measured using optical coherence tomography 
(Stratus OCT, version 4.0.1, Carl Zeiss Meditec, Dublin, Calif., 
USA). A high-resolution radial line scan protocol (1.0 B scans/s, 
512 axial measurements with a resolution of around 10   m) was 
used. On each follow-up visit, possible side effects of the treatment 
(intraocular pressure  6 23 mm Hg, anterior chamber reaction, 
severe lens opacity, vitreous hemorrhage, endophthalmitis, reti-
nal detachment, significant blood pressure increase, thromboem-
bolic events) were ruled out.
 Surgical Procedure 
 Patients treated with monotherapy received intravitreal beva-
cizumab (0.05 ml solution prepared from Avastin 100 mg/4-ml 
vial; Roche, Switzerland) or ranibizumab (0.05 ml of 0.5 mg Lu-
centis, Novartis AG, Basel, Switzerland) through the pars plana 
according to standard procedures  [16] . Patients treated with triple 
therapy received full-fluence PDT with verteporfin (Visudyne; 
Novartis) as follows: a 10-min infusion of verteporfin (6 mg/m 2 
body surface area) followed by activation 5 min later by a 689-nm 
diode laser delivering energy of 50 J/cm2 at an intensity of 600 
mW/cm 2 for 83 s using a spot size of a diameter 1.000   m larger 
than the greatest linear dimension of the lesion. An intravitreal 
injection of bevacizumab or ranibizumab followed by an intravit-
real injection of dexamethasone (0.1 ml of 0.4 mg, Merck Géné-
riques, France) were given within a mean of 16 h after PDT
( 8 1 h), as previously suggested  [14] . Direct light exposure of the 
treated eye was avoided. All injections were administered in the 
operating room with topical anesthesia (Tetracaine, Novartis). 
 Patients were observed according to the physician’s discretion, 
at 1- to 2-month intervals. Criteria for retreatment were presence 
of vascular leakage on angiography or intraretinal fluid or sub-
retinal fluid at optical coherence tomography examination. Total 
follow-up, total number of treatments, number of treatments per 
month (total number of treatments/total follow-up) and mean 
disease-free time (time before second retreatment) in the 2 groups 
were evaluated.
 Statistics 
 Statistical analysis was performed using the Statistical Pack-
age for Social Sciences (version 17.0, SPSS Inc., Chicago, Ill., USA). 
The Student t test and Yates corrected   2 test were used for inter-
group comparisons. The Kaplan-Meier method was used to esti-
mate the retreatment-free time. Intragroup changes were com-
pared by repeated-measures ANOVA with Dunnett correction for 
multiple comparisons. The level of statistical significance was set 
at p  ! 0.05.
 Results 
 Sixty-one eyes (56 patients) had been treated with tri-
ple therapy. Of them, 35 had been treated with ranibi-
zumab, and 26 had been treated with bevacizumab. For-
ty eyes (40 patients) had been treated with monotherapy. 
Of them, 18 had been treated with ranibizumab and 22 
had been treated with bevacizumab. Baseline character-
istics of the study groups are resumed in  table 1 . Nine-
teen cases of occult CNVs and 42 cases of classic CNVs 
were present in the triple-therapy group, while 13 cases 
of occult CNVs and 27 cases of classic CNVs were pres-
ent in the monotherapy group. No significant differenc-
es were present at baseline between the triple-therapy 
group and the monotherapy group regarding age, BCVA 
and FT. 
 No adverse effect was noted during follow-up in any of 
the study groups. During the 12 months after the first 
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treatment, a significant improvement of BCVA when 
compared to baseline was present in both triple-therapy 
and monotherapy groups without significant intergroup 
differences ( table  2 ). In the triple-therapy group, im-
provement during the first 12 months was constant, while 
in the monotherapy group it was more pronounced dur-
ing the first month. A progressive significant improve-
ment of FT was present in both groups. The eyes with 
occult CNV showed a trend toward BCVA and FT im-
provement during the 12 months following the first treat-
ment, although changes did not reach significance.
 No significant difference as concerns the length of fol-
low-up was present between the 2 groups (triple therapy 
14  8 3.4 months vs. monotherapy 16.3  8 4.1 months,
p = 0.09;  table 3 ). The triple-therapy group showed a sig-
nificantly lower total number of treatments during fol-
low-up (1.92  8 0.44 vs. 3.12  8 0.37, p  ! 0.001), a signifi-
cantly lower number of treatments per month (0.13  8 
0.07 vs. 0.19  8 0.15, p = 0.001) and a significantly longer 
time before first retreatment (5.4  8 3.3 vs. 3.6  8 2.5 
months, p = 0.001;  table 3 ). In all cases retreatment had 
been performed with the same modality as at baseline.
 Subgroup Analysis 
 During the 12 months after the first treatment, a non-
significant improvement of BCVA and FT was present in 
the eyes treated with bevacizumab in triple therapy or 
monotherapy and in the eyes treated with ranibizumab 
Table 1.  Baseline characteristics (means 8 SD) of the evaluated groups
Treatment Eyes/
patients
Sex Anti-VEGF, n Age, years CNV characteristics
occult/classic, n
TT 61/56 22 M/34 F 35 TTL/26 TTA 77.287.7 19/42 (31.1/68.9%)
MT 40/40 11 M/19 F 13 ML/17 MA 76.388.1 13/27 (32.5/67.5%)
T T = Eyes treated with triple therapy; MT = eyes treated with monotherapy; TTL = triple therapy with ranibizumab; TTA = triple 
therapy with bevacizumab; ML = monotherapy with ranibizumab; MA = monotherapy with bevacizumab.
Table 2.  BCVA (Early Treatment Diabetic Retinopathy Study logMAR, means 8 standard deviation) and FT (m, means 8 standard 
deviation) at optical coherence tomography in the 2 groups at baseline and during 12 months from first treatment
Baseline Month 1 Month 2 Month 3 Month 6 Month 12
TT BCVA 0.9480.44 0.7380.35 (p = 0.008) 0.6580.38 (p = 0.011) 0.6480.25 (p = 0.011) 0.7380.37 (p = 0.009) 0.7880.53 (p = 0.02)
MT BCVA 1.0980.38 0.8580.42 (p = 0.009) 0.9580.38 (p = 0.011) 0.9580.46 (p = 0.008) 0.9880.42 (p = 0.009) 0.9980.37 (p = 0.03)
TT FT 323894.2 215.3857 (p = 0.001) 220.5861.6 (p = 0.03) 208837.3 (p = 0.02) 209.3847 (p = 0.02) 212.2865.3 (p < 0.001)
MT FT 384.1897.2 243.3847.6 (p = 0.011) 271.3828.3 (p = 0.011) 192.24865.5 (p < 0.001) 203.3849 (p < 0.001) 218.3861.2 (p < 0.001)
p value: significance when compared to baseline. TT = Eyes treated with triple therapy; MT = eyes treated with monotherapy.
Table 3.  Mean follow-up, total number of treatments, number of treatments per month and time before retreatment in the study groups
n Follow-up, months Treatments Treatments per month Time before
retreatment, months
TT 61 14.183.4 (1–26) 1.9280.44 (1–4) 0.1380.07 (0.07–1) 5.483.3 (1–14)
MT 40 16.384.1 (1–27) 3.1280.37 (1–7) 0.1980.15 (0.06–1) 3.682.5 (1–12)
M eans 8 SD, ranges in parentheses; TT = all eyes treated with triple therapy; MT = all eyes treated with monotherapy.
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in triple therapy or monotherapy ( fig. 1 ), without signifi-
cant intergroup differences. No significant difference was 
found among the 4 subgroups as concerns the number of 
treatments during follow-up, the number of treatments 
per month and time before retreatment. 
 Discussion 
 To our knowledge, this is the first study comparing 
ranibizumab or bevacizumab in monotherapy and in tri-
ple therapy in combination with full-fluence PDT and 
intravitreal dexamethasone for the treatment of exuda-
tive AMD. The combination between intravitreal bevaci-
zumab, reduced-fluence PDT and intravitreal dexameth-
asone  [14, 15] , and the combination between standard 
fluence PDT, bevacizumab and intravitreal triamcino-
lone  [17, 18] have previously been shown to determine a 
sustained improvement of both BCVA and FT with a re-
duced number of injections, although no monotherapy 
group was used for comparison. 
 A significant improvement of BCVA and FT was pres-
ent in both monotherapy and triple-therapy groups, 
without significant intergroup differences. PDT acts by 
determining a direct closure of neovascular membranes, 
but initiates an inflammatory response and upregulates 
VEGF and other growth factors  [19] . Anti-VEGF therapy 
targets key mediators of the angiogenic cascade resulting 
in suppression of activity of choroidal neovascular lesions 
due to AMD. Therefore, in combination treatment, PDT 
directly destroys existing CNVs while anti-VEGF drugs 
prevent their further growth and limit the inflammatory 
effects of PDT. A combination therapy of PDT with anti-
angiogenic agents has been shown to be effective in neo-
vascular AMD, especially by prolonging the intervals for 
reinjections  [20, 21] . The anti-inflammatory properties of 
steroids limit any further VEGF increase after PDT  [14] . 
The combination of verteporfin with steroids such as in-
travitreal triamcinolone and dexamethasone has been 
shown to determine a visual acuity improvement with 
few treatments  [22–29] . When compared with a suspen-
sion of triamcinolone, dexamethasone solution presents 
no sustained release, a more rapid clearance from the vit-
reous and a better safety profile as it does not determine 
the increase in intraocular pressure  [14] . Furthermore, it 
has been shown to have antifibrotic, antiproliferative and 
antimigration properties. As previously suggested  [14] , 
we administered dexamethasone and the anti-VEGF 
drug 16 h after PDT in order to prevent the PDT-mediat-
ed overactivation of the inflammatory cascade without 
blocking the therapeutic effects of PDT which depend on 
immunologically mediated processes. 
 In the triple-therapy group, a significantly lower num-
ber of treatments and a significantly longer time be-
fore retreatment were observed. Long-lasting effects are 
limited in PDT monotherapy due to the persisting in-
flammation and edema, and in anti-VEGF monotherapy 
due to the persistence of CNV. Both ranibizumab and be-
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 Fig. 1. Changes of BCVA ( a ) and FT ( b ) over 12 months in the 4 subgroups (means and 95% confidence inter-
vals). TTL = Triple therapy with ranibizumab; TTA = triple therapy with bevacizu mab; ML = monotherapy with 
ranibizumab; MA = monotherapy with bevacizumab; ETDRS = Early Treatment Diabetic Retinopathy Study. 
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vacizumab treatments usually need repeated administra-
tions to achieve and maintain positive results. Twelve-
month results of the Mont Blanc prospective, random-
ized, double-masked, multicenter trial show that com-
bining standard fluence PDT with ranibizumab 0.5 mg 
can deliver BCVA improvements that are noninferior to 
a ranibizumab monotherapy regimen with 3 loading dos-
es followed by injections on a monthly as-needed basis, 
although no significant difference was found between the 
combination and monotherapy groups with regard to the 
proportion of patients with a treatment-free interval of at 
least 3 months duration after month 2  [30] . The reduced 
number of retreatments enjoyed by the triple therapy 
group in our study could be explained by the adjunct of 
dexamethasone, which would blunt the PDT proinflam-
matory effects. A combined triple therapy which allows 
to prolong the intervals for reinjections and to reduce the 
number of intravitreal injections could represent a good 
option in terms of durability, safety and cost. 
 All the eyes with occult CNV showed a trend toward 
visual and anatomic improvement during the first 12 
months after treatment, although this was not statisti-
cally significant. In the past, PDT was considered the 
standard therapy for patients with predominantly classic 
subfoveal CNV due to neovascular AMD  [31, 32] . On the 
other hand, our results are confirmed by the recently re-
ported effectiveness of a combined therapy with PDT and 
intravitreal ranibizumab in occult CNVs  [33, 34] . 
 In this study full-fluence PDT was used, and a reduc-
tion in the number of injections was obtained, as reported 
in studies using reduced-fluence PDT  [14, 15] . Therefore, 
the anti-inflammatory effect of dexamethasone probably 
limited the dose-related side effects of full-fluence PDT.
 In both triple therapy and monotherapy groups, BCVA 
and FT improved not depending on whether bevacizu-
mab or ranibizumab was used, although without signifi-
cant differences. Our data agree with a recent study by 
Fong et al.  [35] , who reported a similar effectiveness of 
both bevacizumab and ranibizumab treatments in stabi-
lizing BCVA loss without differences in BCVA outcome.
 No complication was noted during follow-up in any of 
the study groups. Possible ocular complications following 
intravitreal injections are endophthalmitis, retinal de-
tachment, vitreous hemorrhage and lens injury  [35] while 
systemic adverse effects related to the anti-VEGF drug 
may be secondary to accelerated collateral-vessel closure 
like thromboembolic events  [6, 36–39] . Monthly injec-
tions of anti-VEGF may increase the risk of complica-
tions. Combination therapies could represent a valid ap-
proach to reduce the number of injections. 
 A limitation of our study is the retrospective design. 
However, the population size and the 12-month follow-
up may help support our findings. A prospective study is 
planned to confirm our results.
 In conclusion, treatment of naïve patients with exuda-
tive AMD with triple therapy with bevacizumab or ra-
nibizumab in combination with dexamethasone and 
verteporfin PDT provided similar visual and anatomic 
improvements when compared to anti-VEGF monother-
apy, with a reduced number of injections and a longer 
time before retreatment. Clinical trials are needed to con-
firm our preliminary results.
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